I think the point was that members of the committees bring their own biases and professional knowledge to the table and the discussions. In fact, for the provinces, it's an area of our concern with respect to decisions that are contradictory. Cancer was one in relation to CEDAC recommendations. Introducing conditional listings or more flexibility in terms of providing patients with access to new drugs would assist in giving that flexibility. We've heard about Quebec. There are perhaps social considerations and economic considerations, and those aren't brought into the picture.
On May 9th, 2007. See this statement in context.